Kamada (NASDAQ:KMDA) Downgraded by StockNews.com to “Buy”

StockNews.com downgraded shares of Kamada (NASDAQ:KMDA) from a strong-buy rating to a buy rating in a research note released on Tuesday morning.

Other equities analysts have also issued reports about the stock. Benchmark began coverage on shares of Kamada in a research report on Friday, March 21st. They issued a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 6th.

Kamada Stock Down 0.3 %

KMDA opened at $7.08 on Tuesday. The stock has a market cap of $406.96 million, a price-to-earnings ratio of 25.29, a PEG ratio of 0.97 and a beta of 0.97. Kamada has a 12-month low of $4.74 and a 12-month high of $9.16. The business has a 50 day moving average of $7.19 and a 200-day moving average of $6.28.

Kamada Announces Dividend

The firm also recently announced a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be given a $0.20 dividend. The ex-dividend date of this dividend is Monday, March 17th.

Hedge Funds Weigh In On Kamada

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in Kamada in the 4th quarter valued at about $67,000. Public Employees Retirement System of Ohio acquired a new stake in Kamada during the third quarter worth approximately $77,000. NewEdge Advisors LLC grew its position in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after buying an additional 8,260 shares in the last quarter. Geode Capital Management LLC increased its stake in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 1,549 shares during the period. Finally, Aristides Capital LLC raised its holdings in Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares in the last quarter. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.